{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:14:00Z","timestamp":1793823240302,"version":"4.6.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009393","name":"Kobe Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009393","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.xphs.2024.05.003","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T15:59:35Z","timestamp":1715270375000},"page":"2633-2640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Left-Right Difference in Brain Pharmacokinetics Following Nasal Administration Via One-Site Nostrils"],"prefix":"10.1016","volume":"113","author":[{"given":"Akiko","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-9367","authenticated-orcid":false,"given":"Akiko","family":"Kiriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho","family":"Changung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemasa","family":"Katsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Furubayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.xphs.2024.05.003_bib0001","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/0091-6749(91)90136-C","article-title":"Levocabastine nasal spray better than sodium cromoglycate and placebo in the topical treatment of seasonal allergic rhinitis","volume":"87","author":"Schata","year":"1991","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.xphs.2024.05.003_bib0002","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2147\/TCRM.S1984","article-title":"Fluticasone furoate nasal spray in the treatment of allergic rhinitis","volume":"4","author":"Giavina-Bianchi","year":"2008","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"10.1016\/j.xphs.2024.05.003_bib0003","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1440-1754.2012.02506.x","article-title":"Nocturnal enuresis","volume":"49","author":"Harari","year":"2013","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.xphs.2024.05.003_bib0004","first-page":"227","article-title":"The effect of LHRH agonist therapy in the treatment of endometriosis (English experience)","volume":"225","author":"Jelley","year":"1986","journal-title":"Prog Clin Biol Res"},{"issue":"8","key":"10.1016\/j.xphs.2024.05.003_bib0005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM198802253180805","article-title":"Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial","volume":"318","author":"Henzl","year":"1988","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.xphs.2024.05.003_bib0006","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-016-0641-9","article-title":"Sumatriptan nasal powder: a review in acute treatment of migraine","volume":"76","author":"Al-Salama","year":"2016","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.xphs.2024.05.003_bib0007","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3109\/03639045.2015.1052081","article-title":"Nanoneurotherapeutics approach intended for direct nose to brain delivery","volume":"41","author":"Md","year":"2015","journal-title":"Drug Dev Ind Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2024.05.003_bib0008","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2174\/1567201816666191029122740","article-title":"Drug delivery and targeting to the brain through nasal route: mechanisms, applications and challenges","volume":"16","author":"Kashyap","year":"2019","journal-title":"Curr Drug Deliv"},{"key":"10.1016\/j.xphs.2024.05.003_bib0009","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2014.06.053","article-title":"Quantitative analysis of drug delivery to the brain via nasal route","volume":"189","author":"Kozlovskaya","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.xphs.2024.05.003_bib0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"95","author":"Crowe","year":"2018","journal-title":"Life Sci"},{"issue":"6","key":"10.1016\/j.xphs.2024.05.003_bib0011","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4155\/tde.14.41","article-title":"The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview","volume":"5","author":"Djupesland","year":"2014","journal-title":"Ther Deliv"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2024.05.003_bib0012","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0006-8993(95)00637-6","article-title":"Quantitative analysis of the olfactory pathway for drug delivery to the brain","volume":"692","author":"Thorne","year":"1995","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.xphs.2024.05.003_bib0013","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/mp100029t","article-title":"Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures","volume":"7","author":"Johnson","year":"2010","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2024.05.003_bib0014","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1021\/acs.molpharmaceut.7b00991","article-title":"Delivery of oxytocin to the brain for the treatment of autism spectrum disorder by nasal application","volume":"15","author":"Tanaka","year":"2018","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2024.05.003_bib0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1021\/acs.molpharmaceut.9b00571","article-title":"Transnasal delivery of the peptide agonist specific to neuromedin-U Receptor 2 to the brain for the treatment of obesity","volume":"17","author":"Tanaka","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2024.05.003_bib0016","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.trci.2018.06.012","article-title":"Intranasal rifampicin for Alzheimer's disease prevention","volume":"4","author":"Umeda","year":"2018","journal-title":"Alzheimers Dement (NY)"},{"issue":"10","key":"10.1016\/j.xphs.2024.05.003_bib0017","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3390\/pharmaceutics13101673","article-title":"Direct delivery of ANA-TA9, a peptide capable of A\u03b2 hydrolysis, to the brain by intranasal administration","volume":"13","author":"Hatakawa","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.xphs.2024.05.003_bib0018","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jchromb.2007.09.025","article-title":"Concurrent determination of topotecan and model permeability markers (atenolol, Antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: utility in Caco-2 intestinal absorption studies","volume":"859","author":"Bansal","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"1","key":"10.1016\/j.xphs.2024.05.003_bib0019","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1021\/mp800122b","article-title":"Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay","volume":"6","author":"Thiel-Demby","year":"2009","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2024.05.003_bib0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1093-3263(02)00163-8","article-title":"Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability","volume":"21","author":"Winiwarter","year":"2003","journal-title":"J Mol Graph Model"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2024.05.003_bib0021","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijpharm.2009.05.009","article-title":"The transnasal delivery of 5-fluorouracil to the rat brain is enhanced by acetazolamide (the inhibitor of the secretion of cerebrospinal fluid)","volume":"377","author":"Shingaki","year":"2009","journal-title":"Int J Pharm"},{"issue":"3837","key":"10.1016\/j.xphs.2024.05.003_bib0022","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1126\/science.161.3837.186","article-title":"Human brain: left-right asymmetries in temporal speech region","volume":"161","author":"Geschwind","year":"1968","journal-title":"Science"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924001746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924001746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T06:50:02Z","timestamp":1724741402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924001746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0022354924001746"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.05.003","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Left-Right Difference in Brain Pharmacokinetics Following Nasal Administration Via One-Site Nostrils","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}